Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus R

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have earned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 […]

Related Keywords

United States , Bobakr Azamian , Aziz Mottiwala , Invesco Ltd , Dimensional Fund Advisors , Securities Exchange Commission , Tarsus Pharmaceuticals Stock , Goldman Sachs Group , Tarsus Pharmaceuticals Inc , Tarsus Pharmaceuticals , Barclays , Jefferies Financial Group , News Ratings For Tarsus Pharmaceuticals Daily , Analyst Recommendations For Tarsus Pharmaceuticals , Nasdaq , Charles Schwab Investment Management Inc , Get Free Report , Marketbeat Ratings , Financial Group , Exchange Commission , Fund Advisors , Schwab Investment Management , State Street Corp , Street Corp , Get Free , Tarsus Pharmaceuticals Daily ,